RecruitingPhase 1NCT07278336
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
Studying Malignant tumor of fallopian tubes
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-901(drug)
- Enrollment
- 207 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (8)
- NEXT Oncology - San Antonio /ID# 278606, San Antonio, Texas, United States
- Start Mountain Region /ID# 278609, West Valley City, Utah, United States
- Next Virginia /ID# 278607, Fairfax, Virginia, United States
- The Chaim Sheba Medical Center /ID# 278416, Ramat Gan, Tel Aviv, Israel
- Rambam Health Care Campus /ID# 278418, Haifa, Israel
- Hadassah Medical Center-Hebrew University /ID# 278420, Jerusalem, Israel
- Saitama Medical University International Medical Center /ID# 278437, Hidaka, Saitama, Japan
- Shizuoka Cancer Center /ID# 278538, Sunto-gun, Shizuoka, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07278336 on ClinicalTrials.govOther trials for Malignant tumor of fallopian tubes
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06855706An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 StudyRoswell Park Cancer Institute
- RECRUITINGPHASE2NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT05887609An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05053750TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerM.D. Anderson Cancer Center